BR112018002414A2 - sistema de distribuição de polímero líquido para administração prolongada de fármacos - Google Patents

sistema de distribuição de polímero líquido para administração prolongada de fármacos

Info

Publication number
BR112018002414A2
BR112018002414A2 BR112018002414A BR112018002414A BR112018002414A2 BR 112018002414 A2 BR112018002414 A2 BR 112018002414A2 BR 112018002414 A BR112018002414 A BR 112018002414A BR 112018002414 A BR112018002414 A BR 112018002414A BR 112018002414 A2 BR112018002414 A2 BR 112018002414A2
Authority
BR
Brazil
Prior art keywords
liquid polymer
delivery system
extended drug
liquid
drug delivery
Prior art date
Application number
BR112018002414A
Other languages
English (en)
Other versions
BR112018002414B1 (pt
Inventor
Middleton John
Milton Downing John
Saxena Vipin
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of BR112018002414A2 publication Critical patent/BR112018002414A2/pt
Publication of BR112018002414B1 publication Critical patent/BR112018002414B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

sistema de distribuição de polímero líquido para administração prolongada de fármacos composições farmacêuticas líquidas de polímero com um poliéster líquido biodegradável que tem um grupo terminal de ácido carboxílico, um solvente biocompatível, e um agente farmacêutico ativo são úteis para administração no corpo para prover liberação prolongada de longo prazo do fármaco.
BR112018002414-7A 2015-08-03 2016-08-03 Composição farmacêutica de polímero líquido para administração no corpo de um animal, seu uso para tratar, prover uma terapia para curar ou prevenir uma doença, distúrbio ou outra enfermidade e sistema de distribuição para administração da dita composição BR112018002414B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562200198P 2015-08-03 2015-08-03
US62/200,198 2015-08-03
US201662275407P 2016-01-06 2016-01-06
US62/275,407 2016-01-06
PCT/US2016/045334 WO2017024027A1 (en) 2015-08-03 2016-08-03 Liquid polymer delivery system for extended administration of drugs

Publications (2)

Publication Number Publication Date
BR112018002414A2 true BR112018002414A2 (pt) 2018-09-18
BR112018002414B1 BR112018002414B1 (pt) 2023-11-21

Family

ID=56684769

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018002414-7A BR112018002414B1 (pt) 2015-08-03 2016-08-03 Composição farmacêutica de polímero líquido para administração no corpo de um animal, seu uso para tratar, prover uma terapia para curar ou prevenir uma doença, distúrbio ou outra enfermidade e sistema de distribuição para administração da dita composição

Country Status (20)

Country Link
US (3) US10786515B2 (pt)
EP (2) EP3331495B1 (pt)
JP (1) JP6949820B2 (pt)
KR (1) KR20180030413A (pt)
CN (1) CN107920988B (pt)
AU (1) AU2016302252B2 (pt)
BR (1) BR112018002414B1 (pt)
CA (1) CA2994704A1 (pt)
DK (1) DK3331495T3 (pt)
EA (1) EA036951B1 (pt)
ES (1) ES2836805T3 (pt)
HK (1) HK1255638A1 (pt)
HR (1) HRP20201991T1 (pt)
HU (1) HUE052832T2 (pt)
IL (1) IL257221B (pt)
MX (1) MX2018001499A (pt)
PT (1) PT3331495T (pt)
TW (1) TWI718168B (pt)
WO (1) WO2017024027A1 (pt)
ZA (1) ZA201800591B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008009125A (es) 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
ES2836805T3 (es) 2015-08-03 2021-06-28 Tolmar International Ltd Sistema de administración de polímeros líquidos para la administración extendida de fármacos
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
AR116501A1 (es) 2018-09-25 2021-05-12 Tolmar Int Ltd Sistema de suministro de polímero líquido para administración extendida de drogas
CN109966557A (zh) * 2018-12-05 2019-07-05 博志生物科技有限公司 局部缓释Abaloparatide或相关多肽的GelMA水凝胶的制备方法及应用
US20220362383A1 (en) 2019-09-30 2022-11-17 Tolmar International Limited Liquid polymer compositions and systems for extended delivery of peptides as active pharmaceutical ingredients
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
EP4221688A1 (en) 2020-09-30 2023-08-09 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6197320B1 (en) * 1994-03-11 2001-03-06 Shalaby W. Shalaby Absorbable E-caprolactone polymers and medical devices
US5668288A (en) * 1996-04-16 1997-09-16 Depuy Orthopaedics, Inc. Polyester ionomers for implant fabrication
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
CA2590696A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
MX2008009125A (es) * 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
WO2010085608A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
GB2481018B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
JPWO2012060267A1 (ja) * 2010-11-04 2014-05-12 新日鉄住金化学株式会社 ハードコート層付ポリカーボネート
AU2012304909B2 (en) * 2011-06-10 2017-06-08 Icon Bioscience, Inc. Sustained release formulations for delivery of proteins to the eye and methods of preparing same
CA2852386C (en) * 2011-10-17 2019-05-21 Poly-Med, Inc. Absorbable in situ gel-forming system, method of making and use thereof
ES2836805T3 (es) 2015-08-03 2021-06-28 Tolmar International Ltd Sistema de administración de polímeros líquidos para la administración extendida de fármacos

Also Published As

Publication number Publication date
BR112018002414B1 (pt) 2023-11-21
PT3331495T (pt) 2020-12-07
MX2018001499A (es) 2018-08-01
DK3331495T3 (da) 2020-12-14
HK1255638A1 (zh) 2019-08-23
EP3804698A1 (en) 2021-04-14
IL257221B (en) 2022-01-01
CA2994704A1 (en) 2017-02-09
US20180214459A1 (en) 2018-08-02
HUE052832T2 (hu) 2021-05-28
KR20180030413A (ko) 2018-03-22
US11779589B2 (en) 2023-10-10
US20240066039A1 (en) 2024-02-29
JP6949820B2 (ja) 2021-10-13
ZA201800591B (en) 2021-07-28
ES2836805T3 (es) 2021-06-28
WO2017024027A1 (en) 2017-02-09
EA201890436A1 (ru) 2018-09-28
EP3804698B1 (en) 2024-01-31
CN107920988B (zh) 2021-08-17
US10786515B2 (en) 2020-09-29
CN107920988A (zh) 2018-04-17
TWI718168B (zh) 2021-02-11
JP2018522906A (ja) 2018-08-16
EP3331495A1 (en) 2018-06-13
HRP20201991T1 (hr) 2021-02-05
US20210060036A1 (en) 2021-03-04
AU2016302252A1 (en) 2018-02-22
EP3331495B1 (en) 2020-11-04
TW201717960A (zh) 2017-06-01
EA036951B1 (ru) 2021-01-19
AU2016302252B2 (en) 2022-01-20
IL257221A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
BR112018002414A2 (pt) sistema de distribuição de polímero líquido para administração prolongada de fármacos
TN2014000441A1 (en) A delayed release drug formulation
SG10201808743VA (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
MX364396B (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
EA033537B1 (ru) Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
CL2019001447A1 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos.
BR112013006341A2 (pt) formulações agrícolas líquidas com estabilidade aperfeiçoada
BR112013017750A8 (pt) nanocápsulas com revestimento polimérico
EA201491685A1 (ru) Препарат для инъекций
BR112018075703A2 (pt) microestrutura do ácido hialurônico tendo exce-lentes características de solubilidade
AR116501A1 (es) Sistema de suministro de polímero líquido para administración extendida de drogas
PE20160534A1 (es) Sistema de administracion intrauterina
MY167777A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
CL2016000944A1 (es) Nueva formulación de ganadotropinas
AR097973A1 (es) FORMULACIÓN FARMACÉUTICA QUE COMPRENDE HORMONA LIBERADORA DE GONADOTROPINA (GnRH), UN AGONISTA DE GnRH O UN ANTAGONISTA DE GnRH Y MÉTODO DE TRATAMIENTO
PH12018500304A1 (en) A delyade release drug formulation
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
AR110595A1 (es) Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos
ES2491340B1 (es) Nueva composición de conjugados de chitosan o derivados con tiolactonas
MX369244B (es) Solucion alcoholica estable de alprostadilo.
EA201991594A1 (ru) Депо-препарат
BR112022004856A2 (pt) Composições de polímero líquido e sistemas para administração prolongada de peptídeos como ingredientes farmacêuticos ativos
PE20191462A1 (es) Composicion liquida que contiene pradofloxacina
CL2016000893A1 (es) Sistema de administración intrauterina que comprende una construcción de un cuerpo y dos depósitos, los cuales comprenden un progestágeno donde los depósitos tienen velocidades y tiempos de liberación diferentes
EA201991485A1 (ru) Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/08/2016, OBSERVADAS AS CONDICOES LEGAIS